Posts made in March, 2012

German Scoreboard: Payers 1, Pharma 1

Posted on Thursday, March 29, 2012

AstraZeneca and other biopharmas wait with bated breath for the first drug price tags to emerge from Germany’s new early added-benefit assessment process. So who’s winning as this...

Learn More

Cancer Pathways: A Bitter Pill For Biopharma

Posted on Wednesday, March 28, 2012

One big message from the first experiments with cancer pathways: they’re making it easier to predict therapy winners and losers.  That emerged loud and clear from Real Endpoints’s March...

Learn More

The Healthcare Round-Up: 3/21 -3/28

Posted on Wednesday, March 28, 2012

All eyes are on Capitol Hill this week as the Supremes hear oral arguments in one of the most important –and politicized—cases in decades: the constitutionality of the Affordable Care Act, the signature piece...

Learn More

Is France Creating Its Own NICE?

Posted on Monday, March 26, 2012

Sort of. It seems that the French are getting more comfortable with the idea of calling health-economics by its real name, and of carrying out explicit cost-effectiveness evaluations a la NICE in the UK....

Learn More

The Healthcare Round-Up: 3/14 – 3/21

Posted on Thursday, March 22, 2012

Put a spring in your step and read Real Endpoints’s weekly round-up of reimbursement related news. Overseeing Cancer Drug Regimens: Here’s a scary find.  On March 16 researchers from Medco Research...

Learn More

The Healthcare Round-Up: 3/7 – 3/13

Posted on Wednesday, March 14, 2012

The Legality of Co-pay cards: It’s no secret co-pay cards are a contentious issue; now, they’ve been taken to the courts. Last week, the consumer advocacy group, Community Catalyst, filed suit against 8 drug...

Learn More

The Healthcare Round-Up: 2/28 – 3/6

Posted on Tuesday, March 6, 2012

Blue Shield of CA Seeks Damages from Physician Group: Last week Blue Shield of California filed for $10.5 million in damages from Monarch HealthCare, since last fall a division of UnitedHealthcare’s Optum....

Learn More

Why Value-Based Pricing May Be Dead

Posted on Friday, March 2, 2012

Perhaps it was too good to be true.  A value-based approach to pricing branded medicines that would increase access and improve outcomes, but also control costs….and stimulate innovation by keeping...

Learn More